Sana Biotechnology

### Executive Summary Sana Biotechnology raised $453.8M in a private placement, with Lockheed Martin Ventures and Bessemer Venture Partners listed as related persons. The large capital raise in synthetic biology and intracellular mRNA delivery signals strong investor confidence in the company's platform. ### Investor Edge Monitor for subsequent amendments (Form D/A) which could reveal additional investors or changes in terms, and watch for any public announcements regarding partnerships or clinical milestones that may leverage this capital. ### Sector capital positioning This significant private capital infusion into synthetic biology and mRNA delivery underscores sustained investor appetite for transformative biotech platforms, potentially catalyzing further deal flow in the sector. ### Convergence Signals No clear public signals such as patents, contracts, or legislation are evident from the filing data alone. However, the involvement of Lockheed Martin Ventures suggests potential defense or aerospace applications. ### Key Takeaways - Sana Biotechnology raised $453.8M in a private placement, a substantial amount for a private biotech. - Related persons include Lockheed Martin Ventures and Bessemer Venture Partners, indicating strategic investors. - First sale date of 2021-10-12 suggests a delayed filing, which could be a compliance risk flag. ### Risk Indicators & Flags Potential red flag: First sale date is 2021-10-12, significantly earlier than the expected filing date (given accession year 2024), indicating a late filing. Form type is D not D/A, so no amendment or capital increase noted. ### Verification & References SEC accession number 0001702600-24-20187. Filing date not provided, but first sale date is 2021-10-12. Verify details at SEC EDGAR under Sana Biotechnology company filings.